Pub Date : 2025-09-05DOI: 10.1016/j.bulcan.2025.05.016
Annabelle Sabouret , Manuel Rodrigues
{"title":"Combinaison Durvalumab et Olaparib – Cancer de l’endomètre métastatique première ligne","authors":"Annabelle Sabouret , Manuel Rodrigues","doi":"10.1016/j.bulcan.2025.05.016","DOIUrl":"10.1016/j.bulcan.2025.05.016","url":null,"abstract":"","PeriodicalId":9365,"journal":{"name":"Bulletin Du Cancer","volume":"112 10","pages":"Pages 1079-1081"},"PeriodicalIF":0.8,"publicationDate":"2025-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145008649","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
<div><h3>Introduction</h3><div>En France, plusieurs stratégies nationales évoquent l’importance de repérer et d’accompagner les proches aidants. Étant donné l’impact multidimensionnel majeur de la situation d’aidance en cancérologie, le centre de lutte contre le cancer (CLCC) de Lyon, a implémenté une consultation dédiée à l’évaluation des besoins des proches aidants et à leur accompagnement. La présente étude vise à recueillir l’adhésion des proches aidants à cette consultation et à décrire ses spécificités.</div></div><div><h3>Méthode</h3><div>Les données ont été recueillies à l’aide d’auto-questionnaires et de formulaires de récolte de données.</div></div><div><h3>Résultats</h3><div>Le taux d’adhésion des 45 participants est élevé (96 %). Ils sont majoritairement venus sur recommandation des professionnels du centre ou grâce à la communication autour de la consultation, avec pour principal motif de faire « le point sur sa situation avec des professionnels ». Deux besoins sont ressortis de la consultation, liés au « soutien psychologique ou psychiatrique » et à « l’information sur les traitements et/ou l’organisation des soins du proche malade ». Pour répondre à ces besoins, les proches aidants ont été orientés majoritairement vers des professionnels (ex. médecins, psychologues) ou des associations.</div></div><div><h3>Conclusion</h3><div>L’accompagnement des proches aidants en cancérologie est une réelle préoccupation dans le cadre des parcours de santé et de soins et représente un enjeu de santé publique majeur en termes de prévention. Cette étude révèle une adhésion élevée des proches aidants à une consultation dédiée. Elle fournit des éléments encourageants pour poursuivre son développement et proposer aux proches aidants un accompagnement ajusté à leurs besoins.</div></div><div><h3>Introduction</h3><div>In France, several national strategies have highlighted the importance of identifying and supporting informal caregivers. Given the major multidimensional impact of the caregiving situation in cancerology, the Cancer Center in Lyon, has set up a consultation dedicated to assessing the needs of informal caregivers and providing them with support. The aim of the current study is to assess the uptake of this consultation by informal caregivers and to describe its specific features.</div></div><div><h3>Method</h3><div>Data were collected using self-questionnaires and data collection forms.</div></div><div><h3>Results</h3><div>The 45 participants had a high take-up rate (96%). Most of them came on the recommendation of the center's professionals or thanks to the communication surrounding the consultation, with the main reason being to “take stock of their situation with professionals”. Two needs emerged from the consultation, relating to ‘psychological or psychiatric support’ and ‘information on treatments and/or the organisation of care for their sick relative’. To meet these needs, the majority of informal caregivers were referred to professio
{"title":"Évaluation d’une consultation dédiée aux proches aidants dans un centre de lutte contre le cancer","authors":"Noémie Escot , Anne-Sophie Baudry , Clémence Bouffay , Marion Delpuech , Emilie Charton , Christophe Bouvier , Matthias Schell , Yohan Fayet , Valentine Baudry , Mauricio Fuentes-Vallejo , Béatrice Fervers , Magali Girodet , Véronique Christophe","doi":"10.1016/j.bulcan.2025.05.015","DOIUrl":"10.1016/j.bulcan.2025.05.015","url":null,"abstract":"<div><h3>Introduction</h3><div>En France, plusieurs stratégies nationales évoquent l’importance de repérer et d’accompagner les proches aidants. Étant donné l’impact multidimensionnel majeur de la situation d’aidance en cancérologie, le centre de lutte contre le cancer (CLCC) de Lyon, a implémenté une consultation dédiée à l’évaluation des besoins des proches aidants et à leur accompagnement. La présente étude vise à recueillir l’adhésion des proches aidants à cette consultation et à décrire ses spécificités.</div></div><div><h3>Méthode</h3><div>Les données ont été recueillies à l’aide d’auto-questionnaires et de formulaires de récolte de données.</div></div><div><h3>Résultats</h3><div>Le taux d’adhésion des 45 participants est élevé (96 %). Ils sont majoritairement venus sur recommandation des professionnels du centre ou grâce à la communication autour de la consultation, avec pour principal motif de faire « le point sur sa situation avec des professionnels ». Deux besoins sont ressortis de la consultation, liés au « soutien psychologique ou psychiatrique » et à « l’information sur les traitements et/ou l’organisation des soins du proche malade ». Pour répondre à ces besoins, les proches aidants ont été orientés majoritairement vers des professionnels (ex. médecins, psychologues) ou des associations.</div></div><div><h3>Conclusion</h3><div>L’accompagnement des proches aidants en cancérologie est une réelle préoccupation dans le cadre des parcours de santé et de soins et représente un enjeu de santé publique majeur en termes de prévention. Cette étude révèle une adhésion élevée des proches aidants à une consultation dédiée. Elle fournit des éléments encourageants pour poursuivre son développement et proposer aux proches aidants un accompagnement ajusté à leurs besoins.</div></div><div><h3>Introduction</h3><div>In France, several national strategies have highlighted the importance of identifying and supporting informal caregivers. Given the major multidimensional impact of the caregiving situation in cancerology, the Cancer Center in Lyon, has set up a consultation dedicated to assessing the needs of informal caregivers and providing them with support. The aim of the current study is to assess the uptake of this consultation by informal caregivers and to describe its specific features.</div></div><div><h3>Method</h3><div>Data were collected using self-questionnaires and data collection forms.</div></div><div><h3>Results</h3><div>The 45 participants had a high take-up rate (96%). Most of them came on the recommendation of the center's professionals or thanks to the communication surrounding the consultation, with the main reason being to “take stock of their situation with professionals”. Two needs emerged from the consultation, relating to ‘psychological or psychiatric support’ and ‘information on treatments and/or the organisation of care for their sick relative’. To meet these needs, the majority of informal caregivers were referred to professio","PeriodicalId":9365,"journal":{"name":"Bulletin Du Cancer","volume":"112 10","pages":"Pages 1113-1125"},"PeriodicalIF":0.8,"publicationDate":"2025-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145008608","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-09-05DOI: 10.1016/j.bulcan.2025.05.012
Anmar Al-Taie, Jouwana Elmasri
The scientific community has become more enthusiastic about ketogenic diet (KD) to improve the outcomes in medical conditions, including cancer by exploiting the reprogramed metabolism of cancer cells, making the diet a promising candidate as an adjuvant cancer therapy. From this perspective, the aim of this study was to provide a broad overview covering the therapeutic effects, evaluating the clinical evidence of clinical studies underlying the implementation of the KD in the context of cancer treatment and prognosis. A scoping literature search between the years 1990 and 2023 was carried out by using PRISMA guidelines and searching through different databases of the clinical studies supporting the effectiveness and benefits of KD in various carcinomas that could provide findings of evidence on the prognosis and clinical outcomes of cancer treatment. A total of 23 cancer-related publications were included, 12 of which focused on brain cancer particularly glioblastoma multiforme (GBM), 4 on both breast and ovarian cancers, and 3 on pancreatic cancer. A total of 10 publications were reported as clinical trials regarding cancers of the brain (4 studies), breast (2 studies), and ovarian (4 studies). Case report studies were reported in 3 publications for brain cancer, and 2 publications for breast cancer. Nearly almost of the studies found that there was a potential role of KD in the prognosis of cancer treatment. The current review suggests that cancer patients may get favorable effects from the implementation of KD to support clinical outcomes of cancer treatment.
{"title":"Prospects of the therapeutic approaches of ketogenic diet on the clinical outcomes of cancer: A scoping review","authors":"Anmar Al-Taie, Jouwana Elmasri","doi":"10.1016/j.bulcan.2025.05.012","DOIUrl":"10.1016/j.bulcan.2025.05.012","url":null,"abstract":"<div><div>The scientific community has become more enthusiastic about ketogenic diet (KD) to improve the outcomes in medical conditions, including cancer by exploiting the reprogramed metabolism of cancer cells, making the diet a promising candidate as an adjuvant cancer therapy. From this perspective, the aim of this study was to provide a broad overview covering the therapeutic effects, evaluating the clinical evidence of clinical studies underlying the implementation of the KD in the context of cancer treatment and prognosis. A scoping literature search between the years 1990 and 2023 was carried out by using PRISMA guidelines and searching through different databases of the clinical studies supporting the effectiveness and benefits of KD in various carcinomas that could provide findings of evidence on the prognosis and clinical outcomes of cancer treatment. A total of 23 cancer-related publications were included, 12 of which focused on brain cancer particularly glioblastoma multiforme (GBM), 4 on both breast and ovarian cancers, and 3 on pancreatic cancer. A total of 10 publications were reported as clinical trials regarding cancers of the brain (4 studies), breast (2 studies), and ovarian (4 studies). Case report studies were reported in 3 publications for brain cancer, and 2 publications for breast cancer. Nearly almost of the studies found that there was a potential role of KD in the prognosis of cancer treatment. The current review suggests that cancer patients may get favorable effects from the implementation of KD to support clinical outcomes of cancer treatment.</div></div>","PeriodicalId":9365,"journal":{"name":"Bulletin Du Cancer","volume":"112 11","pages":"Pages 1318-1333"},"PeriodicalIF":0.8,"publicationDate":"2025-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145008606","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-09-05DOI: 10.1016/j.bulcan.2025.07.007
Audrey Grain , Céline Falaise , Virginie Gandemer , Céline Khouri , Laura Olivier , Audrey Petit , Alexandre Theron , Charlotte Garczynski , Julia Vergier , Caroline Oudot , Vanessa Vautier
Les ateliers d’harmonisation du comité leucémie de la Société française des cancers de l’enfant (SFCE) ont pour but d’établir des recommandations pratiques établies, d’une part, à partir des données de la littérature et des recommandations internationales et, d’autre part, par consensus en l’absence de données formellement prouvées. Les adolescentes pubères et jeunes adultes qui bénéficient d’un traitement intensif par chimiothérapie peuvent présenter des saignements utérins abondants. Les données collectées auprès de 25 centres ont montré une grande hétérogénéité de prise en charge des saignements utérins abondants en situation aiguë ou en prophylaxie. L’analyse de la littérature montre que compte tenu de l’incidence de l’aménorrhée spontanée en cours de traitement par chimiothérapie, il n’y a pas d’indication à une prévention primaire systématique des saignements utérins abondants chez les patientes traitées pour une leucémie. En cas de saignements utérins abondants avérés, un traitement non hormonal et un traitement hormonal peuvent être instaurés en urgence. En prophylaxie secondaire, différents traitements hormonaux ayant pour objectif la mise en aménorrhée prophylactique peuvent être discutés.
The harmonization workshops of the leukemia committee of the Société française des cancers de l’enfant (SFCE) aim to establish practical recommendations based on the one hand, on data from the literature and international recommendations and, on the other hand, by consensus in the absence of formally proven data. Adolescent pubescent girls and young adults undergoing intensive chemotherapy treatment may present with heavy uterine bleeding (HUB). Data collected from 25 French centers showed that there was considerable heterogeneity in the management of HUB either in prophylaxis or curative strategy. Analysis of the literature showed that, given the incidence of spontaneous amenorrhea during chemotherapy treatment, there is no indication for systematic prophylaxis of HUB in patients treated for leukemia. In case of proven HUB, non-hormonal treatment and hormonal treatment can be introduced as a matter of urgency. For secondary prophylaxis, various hormonal treatments aiming at achieving prophylactic amenorrhea may be discussed.
{"title":"Prise en charge des saignements utérins abondants chez les patientes traitées pour une leucémie aiguë : recommandations du comité leucémie de la SFCE","authors":"Audrey Grain , Céline Falaise , Virginie Gandemer , Céline Khouri , Laura Olivier , Audrey Petit , Alexandre Theron , Charlotte Garczynski , Julia Vergier , Caroline Oudot , Vanessa Vautier","doi":"10.1016/j.bulcan.2025.07.007","DOIUrl":"10.1016/j.bulcan.2025.07.007","url":null,"abstract":"<div><div>Les ateliers d’harmonisation du comité leucémie de la Société française des cancers de l’enfant (SFCE) ont pour but d’établir des recommandations pratiques établies, d’une part, à partir des données de la littérature et des recommandations internationales et, d’autre part, par consensus en l’absence de données formellement prouvées. Les adolescentes pubères et jeunes adultes qui bénéficient d’un traitement intensif par chimiothérapie peuvent présenter des saignements utérins abondants. Les données collectées auprès de 25 centres ont montré une grande hétérogénéité de prise en charge des saignements utérins abondants en situation aiguë ou en prophylaxie. L’analyse de la littérature montre que compte tenu de l’incidence de l’aménorrhée spontanée en cours de traitement par chimiothérapie, il n’y a pas d’indication à une prévention primaire systématique des saignements utérins abondants chez les patientes traitées pour une leucémie. En cas de saignements utérins abondants avérés, un traitement non hormonal et un traitement hormonal peuvent être instaurés en urgence. En prophylaxie secondaire, différents traitements hormonaux ayant pour objectif la mise en aménorrhée prophylactique peuvent être discutés.</div></div><div><div>The harmonization workshops of the leukemia committee of the Société française des cancers de l’enfant (SFCE) aim to establish practical recommendations based on the one hand, on data from the literature and international recommendations and, on the other hand, by consensus in the absence of formally proven data. Adolescent pubescent girls and young adults undergoing intensive chemotherapy treatment may present with heavy uterine bleeding (HUB). Data collected from 25 French centers showed that there was considerable heterogeneity in the management of HUB either in prophylaxis or curative strategy. Analysis of the literature showed that, given the incidence of spontaneous amenorrhea during chemotherapy treatment, there is no indication for systematic prophylaxis of HUB in patients treated for leukemia. In case of proven HUB, non-hormonal treatment and hormonal treatment can be introduced as a matter of urgency. For secondary prophylaxis, various hormonal treatments aiming at achieving prophylactic amenorrhea may be discussed.</div></div>","PeriodicalId":9365,"journal":{"name":"Bulletin Du Cancer","volume":"112 11","pages":"Pages 1342-1352"},"PeriodicalIF":0.8,"publicationDate":"2025-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145008686","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ovarian mature teratomas (OMTs) are the most common benign ovarian tumors in pediatric patients. Management in adolescents can be performed by pediatric (PSs) or gynecologic surgeons (GSs). The aim of this study was to assess the differences in OMT management and the repercussions according to the risk of secondary events.
Design
Based on a multicentric study, we compared patients aged 14 to 18 who underwent surgery for OMT between 2009 and 2022 from the French national pediatric database of OMTs with patients managed by GSs.
Results
In total, 119 patients were included (80 by PSs, 39 by GSs). Differences between teams were noted: (i) tumor marker analysis is systematic by PSs (80%, n = 72) but rare by GSs (18%, n = 7) (P < 0.001), (ii) PSs mostly carried out a laparotomy (78%, n = 62), whereas GSs preferred laparoscopy (90%, n = 35) (P < 0.001), (iii) peroperative rupture was more frequent by GSs (56%, n = 22) than PSs (10%, n = 8) (P < 0.001), (iv) median duration of follow-up increased by PSs (20 months) versus 1 month by GSs (P = 0.001). Ten second events (13% by GSs [n = 5], 6% by PSs [n = 5]) occurred in nine patients, without significant differences (P = 0.151).
Conclusion
A notable difference exists in the management of OMTs between PSs and GSs in our study, GSs may overlook a malignant component in germ cell tumors in adolescents and the risk of metachronous recurrence, reported up to 10–20%. We recommend a compliance to SIOPE 2020 guidelines (Sessa et al., 2020) to avoid rupture of potential malignant tumor and to preserve fertility.
{"title":"Ovarian mature teratomas: Differences in management and outcomes in adolescents cared for by gynecologic and pediatric surgeons","authors":"Iliasse Baatti , Fanny Delehaye , Sabine Sarnacki , Christine Denoual Ziad , Frédéric Hameury , Estelle Aubry , Edouard Habonimana , Solène Joseph , Aurélien Scalabre , Yann Chaussy , Guillaume Podevin , Quentin Ballouhey , Frédéric Lavrand , Matthieu Peycelon , Sabine Irtan , Florent Guérin , Anne Dariel , Claude Borrione , Louise Galmiche , Elodie Haraux , Julien Rod","doi":"10.1016/j.bulcan.2025.04.016","DOIUrl":"10.1016/j.bulcan.2025.04.016","url":null,"abstract":"<div><h3>Background</h3><div>Ovarian mature teratomas (OMTs) are the most common benign ovarian tumors in pediatric patients. Management in adolescents can be performed by pediatric (PSs) or gynecologic surgeons (GSs). The aim of this study was to assess the differences in OMT management and the repercussions according to the risk of secondary events.</div></div><div><h3>Design</h3><div>Based on a multicentric study, we compared patients aged 14 to 18 who underwent surgery for OMT between 2009 and 2022 from the French national pediatric database of OMTs with patients managed by GSs.</div></div><div><h3>Results</h3><div>In total, 119 patients were included (80 by PSs, 39 by GSs). Differences between teams were noted: (i) tumor marker analysis is systematic by PSs (80%, <em>n</em> <!-->=<!--> <!-->72) but rare by GSs (18%, <em>n</em> <!-->=<!--> <!-->7) (<em>P</em> <!--><<!--> <!-->0.001), (ii) PSs mostly carried out a laparotomy (78%, <em>n</em> <!-->=<!--> <!-->62), whereas GSs preferred laparoscopy (90%, <em>n</em> <!-->=<!--> <!-->35) (<em>P</em> <!--><<!--> <!-->0.001), (iii) peroperative rupture was more frequent by GSs (56%, <em>n</em> <!-->=<!--> <!-->22) than PSs (10%, <em>n</em> <!-->=<!--> <!-->8) (<em>P</em> <!--><<!--> <!-->0.001), (iv) median duration of follow-up increased by PSs (20<!--> <!-->months) versus 1<!--> <!-->month by GSs (<em>P</em> <!-->=<!--> <!-->0.001). Ten second events (13% by GSs [<em>n</em> <!-->=<!--> <!-->5], 6% by PSs [<em>n</em> <!-->=<!--> <!-->5]) occurred in nine patients, without significant differences (<em>P</em> <!-->=<!--> <!-->0.151).</div></div><div><h3>Conclusion</h3><div>A notable difference exists in the management of OMTs between PSs and GSs in our study, GSs may overlook a malignant component in germ cell tumors in adolescents and the risk of metachronous recurrence, reported up to 10–20%. We recommend a compliance to SIOPE 2020 guidelines (Sessa et al., 2020) to avoid rupture of potential malignant tumor and to preserve fertility.</div></div>","PeriodicalId":9365,"journal":{"name":"Bulletin Du Cancer","volume":"112 10","pages":"Pages 1103-1112"},"PeriodicalIF":0.8,"publicationDate":"2025-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145008627","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-09-05DOI: 10.1016/j.bulcan.2025.05.018
Vinh-Hoang-Lan Julie Tran , Angelo Paci , Tiphaine Adam de Beaumais , Etienne Rouleau
The effectiveness and tolerability of medicines can vary considerably from person to person, even at the same dose. This variation is influenced by many factors, including constitutional genetic characteristics. In fact, some people have genetic variations that are common and neutral in the population, known as polymorphisms, which can affect drug metabolism or make them more susceptible to certain adverse effects. These variations can lead to dose-dependent toxicity in the case of genetic polymorphisms of metabolic enzymes or hypersensitivity to drugs. Pharmacogenetics therefore examines the specific genetic factors of each patient to understand their sensitivity to treatment and their risk of developing side effects. By enabling proactive adjustment of dosage and/or treatment, pharmacogenetics minimizes the risk of adverse effects and offers promising prospects for a more personalized approach to tumour management. This review will focus on the potential of pharmacogenetics in cancer care, from cancer treatment to supportive care. It will provide an overview of pharmacogenetic recommendations from national and international scientific and professional societies that are currently used in clinical practice. In addition, we will discuss the challenges and perspectives associated with integrating pharmacogenetics into clinical practice for more personalized management of cancer patients.
{"title":"Pharmacogenetics in oncology: Unveiling its potential in treatment personalization and beyond","authors":"Vinh-Hoang-Lan Julie Tran , Angelo Paci , Tiphaine Adam de Beaumais , Etienne Rouleau","doi":"10.1016/j.bulcan.2025.05.018","DOIUrl":"10.1016/j.bulcan.2025.05.018","url":null,"abstract":"<div><div>The effectiveness and tolerability of medicines can vary considerably from person to person, even at the same dose. This variation is influenced by many factors, including constitutional genetic characteristics. In fact, some people have genetic variations that are common and neutral in the population, known as polymorphisms, which can affect drug metabolism or make them more susceptible to certain adverse effects. These variations can lead to dose-dependent toxicity in the case of genetic polymorphisms of metabolic enzymes or hypersensitivity to drugs. Pharmacogenetics therefore examines the specific genetic factors of each patient to understand their sensitivity to treatment and their risk of developing side effects. By enabling proactive adjustment of dosage and/or treatment, pharmacogenetics minimizes the risk of adverse effects and offers promising prospects for a more personalized approach to tumour management. This review will focus on the potential of pharmacogenetics in cancer care, from cancer treatment to supportive care. It will provide an overview of pharmacogenetic recommendations from national and international scientific and professional societies that are currently used in clinical practice. In addition, we will discuss the challenges and perspectives associated with integrating pharmacogenetics into clinical practice for more personalized management of cancer patients.</div></div>","PeriodicalId":9365,"journal":{"name":"Bulletin Du Cancer","volume":"112 11","pages":"Pages 1301-1317"},"PeriodicalIF":0.8,"publicationDate":"2025-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145008617","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"La supervision des externes en chirurgie oncologique à l’ère de la réforme du deuxième cycle : la mise en place d’une pédagogie active","authors":"Delphine Hudry , Gauthier Decanter , Stéphanie Bataille , Nicolas Penel","doi":"10.1016/j.bulcan.2025.05.019","DOIUrl":"10.1016/j.bulcan.2025.05.019","url":null,"abstract":"","PeriodicalId":9365,"journal":{"name":"Bulletin Du Cancer","volume":"112 10","pages":"Pages 1228-1230"},"PeriodicalIF":0.8,"publicationDate":"2025-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145008635","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-09-05DOI: 10.1016/j.bulcan.2025.05.020
Julien Lejeune , Marie Bossard , Hélène Coillot , Evelyne Fouquereau , Philippe Colombat
Introduction
Si beaucoup de publications ont été faites sur le burn-out des oncologues, peu de publications ont été faites sur les oncologues en France et aucune ne s’attache aux marqueurs positifs de leur santé psychologique. Notre étude est une étude nationale qui étudie le rôle du mode d’exercice, les déterminants et les conséquences de marqueurs positifs de la santé psychologique des oncologues en France.
Méthodologie
L’enquête a été diffusée auprès des oncologues (n = 606) par les sociétés savantes ou groupes coopérateurs des différentes spécialités de cancérologie de mai à juillet 2022. Le questionnaire évaluait les relations entre le mode d’exercice, les déterminants et les conséquences sur le travail, la santé des oncologues et les marqueurs positifs de la santé psychologique.
Résultats
Les oncologues français présentent des scores élevés pour les marqueurs positifs de santé psychologique étudiés avec des différences selon la spécialité, le statut et le mode d’exercice. Concernant les déterminants, on retrouve les mêmes, avec des relations inverses, que ceux déjà connus pour le burn-out : impacts négatifs de l’équilibre vie pro/vie perso, du stress perçu, du workaholisme, de la charge de travail, de l’isolement professionnel, impact positif de la reconnaissance au travail et du soutien de la direction. Des résultats importants concernent la relation des facteurs étudiés avec la santé des oncologues, les comportements au travail mais aussi dans la relation avec les patients (impact important sur l’empathie et la compassion dans les soins).
Conclusion
Notre étude met en évidence les facteurs managériaux et organisationnels devant être travaillés pour préserver la santé psychologique des oncologues.
Introduction
While many publications have been made on burnout of oncologists, few publications have been made on oncologists in France, and none focuses on positive markers of their psychological health. Our study is a national study that studies the role of exercise mode, determinants and consequences of positive markers of psychological health of oncologists in France.
Methodology
The survey was disseminated to oncologists (n = 606) by the learned societies or cooperative groups of the different cancer specialties from May to July 2022. The questionnaire assessed relationships between exercise mode, determinants and consequences for work, oncologist health and positive markers of psychological health.
Results
French oncologists have high scores for positive markers of psychological health studied with differences according to speciality, status and mode of exercise. The determinants are the same, with inverse relationships, as those already known for burnout: negative impacts of the pro/personal life balance
{"title":"Santé psychologique des oncologues : déterminants et conséquences dans les soins","authors":"Julien Lejeune , Marie Bossard , Hélène Coillot , Evelyne Fouquereau , Philippe Colombat","doi":"10.1016/j.bulcan.2025.05.020","DOIUrl":"10.1016/j.bulcan.2025.05.020","url":null,"abstract":"<div><h3>Introduction</h3><div>Si beaucoup de publications ont été faites sur le burn-out des oncologues, peu de publications ont été faites sur les oncologues en France et aucune ne s’attache aux marqueurs positifs de leur santé psychologique. Notre étude est une étude nationale qui étudie le rôle du mode d’exercice, les déterminants et les conséquences de marqueurs positifs de la santé psychologique des oncologues en France.</div></div><div><h3>Méthodologie</h3><div>L’enquête a été diffusée auprès des oncologues (<em>n</em> <!-->=<!--> <!-->606) par les sociétés savantes ou groupes coopérateurs des différentes spécialités de cancérologie de mai à juillet 2022. Le questionnaire évaluait les relations entre le mode d’exercice, les déterminants et les conséquences sur le travail, la santé des oncologues et les marqueurs positifs de la santé psychologique.</div></div><div><h3>Résultats</h3><div>Les oncologues français présentent des scores élevés pour les marqueurs positifs de santé psychologique étudiés avec des différences selon la spécialité, le statut et le mode d’exercice. Concernant les déterminants, on retrouve les mêmes, avec des relations inverses, que ceux déjà connus pour le burn-out : impacts négatifs de l’équilibre vie pro/vie perso, du stress perçu, du workaholisme, de la charge de travail, de l’isolement professionnel, impact positif de la reconnaissance au travail et du soutien de la direction. Des résultats importants concernent la relation des facteurs étudiés avec la santé des oncologues, les comportements au travail mais aussi dans la relation avec les patients (impact important sur l’empathie et la compassion dans les soins).</div></div><div><h3>Conclusion</h3><div>Notre étude met en évidence les facteurs managériaux et organisationnels devant être travaillés pour préserver la santé psychologique des oncologues.</div></div><div><h3>Introduction</h3><div>While many publications have been made on burnout of oncologists, few publications have been made on oncologists in France, and none focuses on positive markers of their psychological health. Our study is a national study that studies the role of exercise mode, determinants and consequences of positive markers of psychological health of oncologists in France.</div></div><div><h3>Methodology</h3><div>The survey was disseminated to oncologists (<em>n</em> <!-->=<!--> <!-->606) by the learned societies or cooperative groups of the different cancer specialties from May to July 2022. The questionnaire assessed relationships between exercise mode, determinants and consequences for work, oncologist health and positive markers of psychological health.</div></div><div><h3>Results</h3><div>French oncologists have high scores for positive markers of psychological health studied with differences according to speciality, status and mode of exercise. The determinants are the same, with inverse relationships, as those already known for burnout: negative impacts of the pro/personal life balance","PeriodicalId":9365,"journal":{"name":"Bulletin Du Cancer","volume":"112 10","pages":"Pages 1126-1134"},"PeriodicalIF":0.8,"publicationDate":"2025-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145008663","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-09-04DOI: 10.1016/j.bulcan.2025.06.008
Ludivine Besse , Stéphane Moreau , Michelle Delpy
<div><div>Le myélome multiple est une pathologie de la moelle osseuse dont l’incidence augmente et qui touche une population plutôt âgée et fragile. Cette maladie bénéficie de traitements innovants permettant l’allongement de la durée de vie des patients. Cependant, au cours de la première année de traitement, ils développent de nombreuses infections, menant à 2 % de décès, malgré l’existence de traitements. Grâce à ses nouvelles compétences, l’infirmier en pratiques avancées (IPA) pourrait jouer un rôle nouveau dans la prévention des infections. Nous avons réalisé une étude multicentrique prospective quantitative dans trois centres hospitaliers en France. Pendant deux mois, des questionnaires ont été proposés aux patients atteints de myélome multiple en cours de première année de traitement. Des questions ouvertes et fermées sur les thèmes du risque infectieux, de l’antibioprophylaxie et de la vaccination composaient ce questionnaire. Soixante participants ont répondu. Les résultats montrent un manque de connaissance du risque infectieux de la part des patients, des symptômes qui doivent être signalés, et l’absence d’un parcours spécifique pour une prise en charge efficace. Il a aussi été retrouvé une méconnaissance des noms des traitements prophylactiques recommandés et de leur utilité. Enfin, la stratégie vaccinale est globalement appropriée, à l’exception de la vaccination contre le pneumocoque qui reste moins systématiquement appliquée. Cette étude permet de proposer des préconisations sur le rôle de l’IPA en matière d’éducation thérapeutique dans la connaissance des traitements, le suivi des vaccinations, la coordination de parcours et en se positionnant comme une personne-ressource pour ces patients et tous les acteurs qui l’entourent.</div></div><div><div>Multiple myeloma is a haematologic malignancy of the bone marrow with an increasing incidence, primarily affecting an elderly and frail population. It benefits from innovative treatments that have been shown to extend patient survival. However, 2% of patients die from infections during the first year of treatment, despite the availability of prophylactic treatments. Thanks to their new skills, advanced practice nurses could play a new role in this care. We conducted a prospective quantitative multicenter study in three French hospitals. Over a two-month period, questionnaires were administered to patients with multiple myeloma in the first year of treatment, followed up in three hospitals. The questionnaire consisted of open and closed questions on the themes of infectious risk, antibiotic prophylaxis and vaccination. A total of 60 participants completed the questionnaire. The results show a lack of knowledge on the part of patients of the risk of infection, the symptoms that need to be reported, and the absence of a specific pathway for effective management. There was also a lack of awareness of the names of recommended prophylactic treatments and their usefulness. Finally, the vaccinat
{"title":"Représentation du risque infectieux chez les patients atteints de myélome multiple : une étude prospective multicentrique visant à adapter le rôle des infirmier(e)s en pratique avancée","authors":"Ludivine Besse , Stéphane Moreau , Michelle Delpy","doi":"10.1016/j.bulcan.2025.06.008","DOIUrl":"10.1016/j.bulcan.2025.06.008","url":null,"abstract":"<div><div>Le myélome multiple est une pathologie de la moelle osseuse dont l’incidence augmente et qui touche une population plutôt âgée et fragile. Cette maladie bénéficie de traitements innovants permettant l’allongement de la durée de vie des patients. Cependant, au cours de la première année de traitement, ils développent de nombreuses infections, menant à 2 % de décès, malgré l’existence de traitements. Grâce à ses nouvelles compétences, l’infirmier en pratiques avancées (IPA) pourrait jouer un rôle nouveau dans la prévention des infections. Nous avons réalisé une étude multicentrique prospective quantitative dans trois centres hospitaliers en France. Pendant deux mois, des questionnaires ont été proposés aux patients atteints de myélome multiple en cours de première année de traitement. Des questions ouvertes et fermées sur les thèmes du risque infectieux, de l’antibioprophylaxie et de la vaccination composaient ce questionnaire. Soixante participants ont répondu. Les résultats montrent un manque de connaissance du risque infectieux de la part des patients, des symptômes qui doivent être signalés, et l’absence d’un parcours spécifique pour une prise en charge efficace. Il a aussi été retrouvé une méconnaissance des noms des traitements prophylactiques recommandés et de leur utilité. Enfin, la stratégie vaccinale est globalement appropriée, à l’exception de la vaccination contre le pneumocoque qui reste moins systématiquement appliquée. Cette étude permet de proposer des préconisations sur le rôle de l’IPA en matière d’éducation thérapeutique dans la connaissance des traitements, le suivi des vaccinations, la coordination de parcours et en se positionnant comme une personne-ressource pour ces patients et tous les acteurs qui l’entourent.</div></div><div><div>Multiple myeloma is a haematologic malignancy of the bone marrow with an increasing incidence, primarily affecting an elderly and frail population. It benefits from innovative treatments that have been shown to extend patient survival. However, 2% of patients die from infections during the first year of treatment, despite the availability of prophylactic treatments. Thanks to their new skills, advanced practice nurses could play a new role in this care. We conducted a prospective quantitative multicenter study in three French hospitals. Over a two-month period, questionnaires were administered to patients with multiple myeloma in the first year of treatment, followed up in three hospitals. The questionnaire consisted of open and closed questions on the themes of infectious risk, antibiotic prophylaxis and vaccination. A total of 60 participants completed the questionnaire. The results show a lack of knowledge on the part of patients of the risk of infection, the symptoms that need to be reported, and the absence of a specific pathway for effective management. There was also a lack of awareness of the names of recommended prophylactic treatments and their usefulness. Finally, the vaccinat","PeriodicalId":9365,"journal":{"name":"Bulletin Du Cancer","volume":"112 12","pages":"Pages 1376-1384"},"PeriodicalIF":0.8,"publicationDate":"2025-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145006960","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-09-01DOI: 10.1016/j.bulcan.2025.03.012
Alexandre Quillet , Nicolas Isambert , Thomas Systchenko , Nolwenn Le Stang , Gautier Defossez
{"title":"Représentativité des patients atteints de cancer du poumon : différences entre un registre de cancer populationnel et un centre hospitalier universitaire","authors":"Alexandre Quillet , Nicolas Isambert , Thomas Systchenko , Nolwenn Le Stang , Gautier Defossez","doi":"10.1016/j.bulcan.2025.03.012","DOIUrl":"10.1016/j.bulcan.2025.03.012","url":null,"abstract":"","PeriodicalId":9365,"journal":{"name":"Bulletin Du Cancer","volume":"112 9","pages":"Pages 1061-1064"},"PeriodicalIF":0.8,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144268147","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：